TGF-beta signaling and its targeted therapy in gastrointestinal cancers
The transforming growth factor β (TGFβ) signaling pathway governs physiological homeostasis in the gastrointestinal system and its deregulation can lead to a diverse range of human pathologies including juvenile polyposis syndrome and tumor initiation, progression, and metastasis. In gastrointestina...
Gespeichert in:
Veröffentlicht in: | Discovery medicine 2018-09, Vol.26 (142), p.103-112 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 112 |
---|---|
container_issue | 142 |
container_start_page | 103 |
container_title | Discovery medicine |
container_volume | 26 |
creator | Gotovac, Jovana Ranko Fujihara, Kenji Mark Phillips, Wayne Allen Clemons, Nicholas James |
description | The transforming growth factor β (TGFβ) signaling pathway governs physiological homeostasis in the gastrointestinal system and its deregulation can lead to a diverse range of human pathologies including juvenile polyposis syndrome and tumor initiation, progression, and metastasis. In gastrointestinal malignancies, tumor cells evade the known tumor suppressive effects of TGFβ signaling through frequent inactivation of the pathway. Paradoxically, tumor cells utilize TGFβ-mediated regulation of epithelial-mesenchymal transition and immunomodulation to facilitate the invasive and migratory phenotype of gastrointestinal cancers and avoid immunosurveillance. The dichotomous role of TGFβ as both a tumor suppressor and tumor promoter has highly challenged research efforts to specifically target TGFβ signaling as a cancer therapy. The current preclinical approach is to inhibit TGFβ-mediated generation of a favorable microenvironment for tumor growth, invasion, and metastasis. Here, we overview the alterations of TGFβ signaling and its fundamental biological relevance in gastrointestinal tumorigenesis. We further discuss future perspectives for efficacious molecular targeted treatment of contextual TGFβ tumor-promoting effects in gastrointestinal cancers. |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2130800207</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2130800207</sourcerecordid><originalsourceid>FETCH-LOGICAL-p141t-7ab600dbb6a0280934b736ede4392277394d4c2fadded4751b570160e57257173</originalsourceid><addsrcrecordid>eNo1z81KAzEUBeAgiK3VV5As3Qzc_MxkspRiq1Dopq6Hm8ntGJmmY5Iu-vZWrKuz-Ticc8PmwmpdGatgxu5z_gJQrWrrOzZToKxVsp2z9W69qhwV5DkMEccQB47R81AyL5gGKuR5-aSE05mHyAfMJR1DLJRLuHjeY-wp5Qd2u8cx0-M1F-xj9bpbvlWb7fp9-bKpJqFFqQy6BsA71yDIFqzSzqiGPGllpTRGWe11L_foPXltauFqA6IBqo2sjTBqwZ7_eqd0_D5dRnSHkHsaR4x0POVOCgUtgIRf-nSlJ3cg300pHDCdu__z6geg61PV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2130800207</pqid></control><display><type>article</type><title>TGF-beta signaling and its targeted therapy in gastrointestinal cancers</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Gotovac, Jovana Ranko ; Fujihara, Kenji Mark ; Phillips, Wayne Allen ; Clemons, Nicholas James</creator><creatorcontrib>Gotovac, Jovana Ranko ; Fujihara, Kenji Mark ; Phillips, Wayne Allen ; Clemons, Nicholas James</creatorcontrib><description>The transforming growth factor β (TGFβ) signaling pathway governs physiological homeostasis in the gastrointestinal system and its deregulation can lead to a diverse range of human pathologies including juvenile polyposis syndrome and tumor initiation, progression, and metastasis. In gastrointestinal malignancies, tumor cells evade the known tumor suppressive effects of TGFβ signaling through frequent inactivation of the pathway. Paradoxically, tumor cells utilize TGFβ-mediated regulation of epithelial-mesenchymal transition and immunomodulation to facilitate the invasive and migratory phenotype of gastrointestinal cancers and avoid immunosurveillance. The dichotomous role of TGFβ as both a tumor suppressor and tumor promoter has highly challenged research efforts to specifically target TGFβ signaling as a cancer therapy. The current preclinical approach is to inhibit TGFβ-mediated generation of a favorable microenvironment for tumor growth, invasion, and metastasis. Here, we overview the alterations of TGFβ signaling and its fundamental biological relevance in gastrointestinal tumorigenesis. We further discuss future perspectives for efficacious molecular targeted treatment of contextual TGFβ tumor-promoting effects in gastrointestinal cancers.</description><identifier>EISSN: 1944-7930</identifier><identifier>PMID: 30399328</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; Cell Transformation, Neoplastic - genetics ; Epithelial-Mesenchymal Transition - genetics ; Gastrointestinal Neoplasms - genetics ; Gastrointestinal Neoplasms - pathology ; Gastrointestinal Neoplasms - therapy ; Genes, Tumor Suppressor ; Humans ; Molecular Targeted Therapy - methods ; Signal Transduction - physiology ; Transforming Growth Factor beta - antagonists & inhibitors ; Transforming Growth Factor beta - physiology</subject><ispartof>Discovery medicine, 2018-09, Vol.26 (142), p.103-112</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30399328$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gotovac, Jovana Ranko</creatorcontrib><creatorcontrib>Fujihara, Kenji Mark</creatorcontrib><creatorcontrib>Phillips, Wayne Allen</creatorcontrib><creatorcontrib>Clemons, Nicholas James</creatorcontrib><title>TGF-beta signaling and its targeted therapy in gastrointestinal cancers</title><title>Discovery medicine</title><addtitle>Discov Med</addtitle><description>The transforming growth factor β (TGFβ) signaling pathway governs physiological homeostasis in the gastrointestinal system and its deregulation can lead to a diverse range of human pathologies including juvenile polyposis syndrome and tumor initiation, progression, and metastasis. In gastrointestinal malignancies, tumor cells evade the known tumor suppressive effects of TGFβ signaling through frequent inactivation of the pathway. Paradoxically, tumor cells utilize TGFβ-mediated regulation of epithelial-mesenchymal transition and immunomodulation to facilitate the invasive and migratory phenotype of gastrointestinal cancers and avoid immunosurveillance. The dichotomous role of TGFβ as both a tumor suppressor and tumor promoter has highly challenged research efforts to specifically target TGFβ signaling as a cancer therapy. The current preclinical approach is to inhibit TGFβ-mediated generation of a favorable microenvironment for tumor growth, invasion, and metastasis. Here, we overview the alterations of TGFβ signaling and its fundamental biological relevance in gastrointestinal tumorigenesis. We further discuss future perspectives for efficacious molecular targeted treatment of contextual TGFβ tumor-promoting effects in gastrointestinal cancers.</description><subject>Animals</subject><subject>Cell Transformation, Neoplastic - genetics</subject><subject>Epithelial-Mesenchymal Transition - genetics</subject><subject>Gastrointestinal Neoplasms - genetics</subject><subject>Gastrointestinal Neoplasms - pathology</subject><subject>Gastrointestinal Neoplasms - therapy</subject><subject>Genes, Tumor Suppressor</subject><subject>Humans</subject><subject>Molecular Targeted Therapy - methods</subject><subject>Signal Transduction - physiology</subject><subject>Transforming Growth Factor beta - antagonists & inhibitors</subject><subject>Transforming Growth Factor beta - physiology</subject><issn>1944-7930</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1z81KAzEUBeAgiK3VV5As3Qzc_MxkspRiq1Dopq6Hm8ntGJmmY5Iu-vZWrKuz-Ticc8PmwmpdGatgxu5z_gJQrWrrOzZToKxVsp2z9W69qhwV5DkMEccQB47R81AyL5gGKuR5-aSE05mHyAfMJR1DLJRLuHjeY-wp5Qd2u8cx0-M1F-xj9bpbvlWb7fp9-bKpJqFFqQy6BsA71yDIFqzSzqiGPGllpTRGWe11L_foPXltauFqA6IBqo2sjTBqwZ7_eqd0_D5dRnSHkHsaR4x0POVOCgUtgIRf-nSlJ3cg300pHDCdu__z6geg61PV</recordid><startdate>201809</startdate><enddate>201809</enddate><creator>Gotovac, Jovana Ranko</creator><creator>Fujihara, Kenji Mark</creator><creator>Phillips, Wayne Allen</creator><creator>Clemons, Nicholas James</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201809</creationdate><title>TGF-beta signaling and its targeted therapy in gastrointestinal cancers</title><author>Gotovac, Jovana Ranko ; Fujihara, Kenji Mark ; Phillips, Wayne Allen ; Clemons, Nicholas James</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p141t-7ab600dbb6a0280934b736ede4392277394d4c2fadded4751b570160e57257173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Cell Transformation, Neoplastic - genetics</topic><topic>Epithelial-Mesenchymal Transition - genetics</topic><topic>Gastrointestinal Neoplasms - genetics</topic><topic>Gastrointestinal Neoplasms - pathology</topic><topic>Gastrointestinal Neoplasms - therapy</topic><topic>Genes, Tumor Suppressor</topic><topic>Humans</topic><topic>Molecular Targeted Therapy - methods</topic><topic>Signal Transduction - physiology</topic><topic>Transforming Growth Factor beta - antagonists & inhibitors</topic><topic>Transforming Growth Factor beta - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gotovac, Jovana Ranko</creatorcontrib><creatorcontrib>Fujihara, Kenji Mark</creatorcontrib><creatorcontrib>Phillips, Wayne Allen</creatorcontrib><creatorcontrib>Clemons, Nicholas James</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Discovery medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gotovac, Jovana Ranko</au><au>Fujihara, Kenji Mark</au><au>Phillips, Wayne Allen</au><au>Clemons, Nicholas James</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TGF-beta signaling and its targeted therapy in gastrointestinal cancers</atitle><jtitle>Discovery medicine</jtitle><addtitle>Discov Med</addtitle><date>2018-09</date><risdate>2018</risdate><volume>26</volume><issue>142</issue><spage>103</spage><epage>112</epage><pages>103-112</pages><eissn>1944-7930</eissn><abstract>The transforming growth factor β (TGFβ) signaling pathway governs physiological homeostasis in the gastrointestinal system and its deregulation can lead to a diverse range of human pathologies including juvenile polyposis syndrome and tumor initiation, progression, and metastasis. In gastrointestinal malignancies, tumor cells evade the known tumor suppressive effects of TGFβ signaling through frequent inactivation of the pathway. Paradoxically, tumor cells utilize TGFβ-mediated regulation of epithelial-mesenchymal transition and immunomodulation to facilitate the invasive and migratory phenotype of gastrointestinal cancers and avoid immunosurveillance. The dichotomous role of TGFβ as both a tumor suppressor and tumor promoter has highly challenged research efforts to specifically target TGFβ signaling as a cancer therapy. The current preclinical approach is to inhibit TGFβ-mediated generation of a favorable microenvironment for tumor growth, invasion, and metastasis. Here, we overview the alterations of TGFβ signaling and its fundamental biological relevance in gastrointestinal tumorigenesis. We further discuss future perspectives for efficacious molecular targeted treatment of contextual TGFβ tumor-promoting effects in gastrointestinal cancers.</abstract><cop>United States</cop><pmid>30399328</pmid><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | EISSN: 1944-7930 |
ispartof | Discovery medicine, 2018-09, Vol.26 (142), p.103-112 |
issn | 1944-7930 |
language | eng |
recordid | cdi_proquest_miscellaneous_2130800207 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
subjects | Animals Cell Transformation, Neoplastic - genetics Epithelial-Mesenchymal Transition - genetics Gastrointestinal Neoplasms - genetics Gastrointestinal Neoplasms - pathology Gastrointestinal Neoplasms - therapy Genes, Tumor Suppressor Humans Molecular Targeted Therapy - methods Signal Transduction - physiology Transforming Growth Factor beta - antagonists & inhibitors Transforming Growth Factor beta - physiology |
title | TGF-beta signaling and its targeted therapy in gastrointestinal cancers |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T01%3A53%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TGF-beta%20signaling%20and%20its%20targeted%20therapy%20in%20gastrointestinal%20cancers&rft.jtitle=Discovery%20medicine&rft.au=Gotovac,%20Jovana%20Ranko&rft.date=2018-09&rft.volume=26&rft.issue=142&rft.spage=103&rft.epage=112&rft.pages=103-112&rft.eissn=1944-7930&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E2130800207%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2130800207&rft_id=info:pmid/30399328&rfr_iscdi=true |